Results 161 to 170 of about 7,554 (201)

Slow Down and Survive: Enigmatic Immunoregulation by BTLA and HVEM

Annual Review of Immunology, 2010
B and T lymphocyte associated (BTLA) is an Ig domain superfamily protein with cytoplasmic immunoreceptor tyrosine-based inhibitory motifs. Its ligand, herpesvirus entry mediator (HVEM), is a tumor necrosis factor receptor superfamily member. The unique interaction between BTLA and HVEM allows for a system of bidirectional signaling that must be ...
Theresa L, Murphy, Kenneth M, Murphy
openaire   +2 more sources

BTLA regulates HVEM signaling in lymphocytes (50.22)

The Journal of Immunology, 2010
Abstract The binding partner of the co-inhibitory receptor, BTLA (B and T Lymphocyte Attenuator) is the co-stimulatory receptor, HVEM (Herpes Virus Entry Mediator). We explored the biological relevance of these two opposing receptor binding partners on lymphocyte activity.
Jill Calemine-Fenaux, Leah Hutchinson, Andrew Vendel, Dan Eaton   +3 more
openaire   +1 more source

BTLA and HVEM Cross Talk Regulates Inhibition and Costimulation

2006
Recently a new inhibitory immunoglobulin domain-containing lymphocyte receptor was identified on the basis of its T helper 1 (T(H)1)-selective expression in murine T cell lines, which was named B and T lymphocyte attenuator (BTLA). Several groups have confirmed the initial characterization of BTLA as an inhibitory receptor, which was initially inferred
Maya, Gavrieli, John, Sedy, Christopher A, Nelson, Kenneth M, Murphy   +3 more
openaire   +2 more sources

The role of the BTLA–HVEM complex in the pathogenesis of breast cancer

Breast Cancer
Breast cancer (BC) is widely recognized as a prevalent contributor to cancer mortality and ranks as the second most prevalent form of cancer among women across the globe. Hence, the development of innovative therapeutic strategies is imperative to effectively manage BC. The B- and T-lymphocyte attenuator (BTLA)-Herpesvirus entry mediator (HVEM) complex
openaire   +2 more sources

Up-regulation of BTLA expression in myeloid dendritic cells associated with the treatment outcome of neonatal sepsis

Molecular Immunology, 2021
Jing Jia, Jun-Fa Xu, Mei Shang
exaly  

Association between BTLA polymorphisms and susceptibility to esophageal squamous cell carcinoma in the Chinese population

Journal of Clinical Laboratory Analysis, 2020
Rui Cao, Shuchen Chen, Weifeng Tang
exaly  

BTLA ANTIBODIES

2020
DAVIS SIMON JOHN, CORNALL RICHARD JOHN, PALUCH CHRISTOPHER DOUGLAS   +2 more
openaire   +4 more sources

ANTI-BTLA ANTIBODY

2020
WU HAI, YAO JIAN, YAO SHENG, FENG HUI, ZHANG JING, ZHOU YUEHUA   +5 more
openaire   +4 more sources

Detection of protein on BTLAlow cells and in vivo antibody-mediated down-modulation of BTLA on lymphoid and myeloid cells of C57BL/6 and BALB/c BTLA allelic variants

Immunobiology, 2010
Jose-Ignacio Rodríguez-Barbosa, Maria-Luisa del Rio   +1 more
exaly  

CpG-ODN-induced sustained expression of BTLA mediating selective inhibition of human B cells

Journal of Molecular Medicine, 2012
Laurent Derre, Emilie Mamessier, Daniel Olive   +2 more
exaly